Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humacyte, Inc. (HUMAW) SEC filings page on Stock Titan provides access to the company’s public regulatory disclosures, with AI-powered summaries to help interpret complex documents. Humacyte is a biotechnology company focused on universally implantable bioengineered human tissues and organs, and its filings give detailed insight into its financing structure, warrant terms, and status as an emerging growth company.
Investors and researchers can review Humacyte’s current reports on Form 8-K, which describe material events such as amendments to its Revenue Interest Purchase Agreement. These filings outline repayment obligations, restricted cash requirements for the benefit of the financing agent, and the terms of an optional call feature that allows Humacyte to repurchase revenue interests at a defined repurchase price, with a portion potentially payable in common stock if specified conditions are met.
On this page, users can also track information related to Humacyte’s redeemable warrants listed on The Nasdaq Stock Market LLC under the symbol HUMAW, where each whole warrant is exercisable for one share of common stock at a stated exercise price. Stock Titan’s AI tools summarize key points from filings, highlight important sections, and clarify technical language, helping users understand how these documents relate to Humacyte’s capital structure and biological products business.
Filings are updated from the SEC’s EDGAR system, so new 8-Ks and other reportable documents appear as they are made public. This makes it easier to locate disclosures about financial obligations, warrant terms, and other regulatory information that shape the risk profile and corporate structure of Humacyte, Inc.
Humacyte, Inc. is asking stockholders at its virtual annual meeting on June 9, 2026 to approve six items, including electing three Class II directors and an advisory vote on executive pay and its frequency. Stockholders will also vote on ratifying PricewaterhouseCoopers LLP as auditor for 2026 and increasing authorized common stock from 350,000,000 to 550,000,000 shares via a charter amendment. Shares outstanding were 222,019,108 as of April 23, 2026, the record date. The proxy outlines governance practices, committee structures, and 2025 compensation, including bonuses paid at 80% of target and significant stock option and RSU grants to senior executives.
Humacyte, Inc. is asking stockholders at its virtual annual meeting on June 9, 2026 to approve six items, including electing three Class II directors and an advisory vote on executive pay and its frequency. Stockholders will also vote on ratifying PricewaterhouseCoopers LLP as auditor for 2026 and increasing authorized common stock from 350,000,000 to 550,000,000 shares via a charter amendment. Shares outstanding were 222,019,108 as of April 23, 2026, the record date. The proxy outlines governance practices, committee structures, and 2025 compensation, including bonuses paid at 80% of target and significant stock option and RSU grants to senior executives.
Humacyte, Inc. and Fresenius Medical Care have amended their 2018 distribution agreement for Symvess, an acellular tissue engineered vessel. Humacyte now has exclusive rights to distribute Symvess outside the U.S., while Fresenius Medical Care Holdings, Inc. will receive low-single-digit royalties on ex-U.S. net sales.
Existing terms for U.S. distribution remain unchanged. Fresenius Medical Care Holdings, Inc. and its parent, Fresenius Medical Care, report beneficial ownership of 18,312,735 shares of Humacyte common stock, representing 8.4% of the class, all with shared voting and dispositive power.
Humacyte, Inc. and Fresenius Medical Care have amended their 2018 distribution agreement for Symvess, an acellular tissue engineered vessel. Humacyte now has exclusive rights to distribute Symvess outside the U.S., while Fresenius Medical Care Holdings, Inc. will receive low-single-digit royalties on ex-U.S. net sales.
Existing terms for U.S. distribution remain unchanged. Fresenius Medical Care Holdings, Inc. and its parent, Fresenius Medical Care, report beneficial ownership of 18,312,735 shares of Humacyte common stock, representing 8.4% of the class, all with shared voting and dispositive power.
Humacyte, Inc. entered a Third Amendment to its distribution agreement with Fresenius Medical Care, giving Humacyte the sole right to develop, manage regulatory matters for, and commercialize its 6 millimeter acellular tissue engineered vessel, branded Symvess, on a worldwide basis.
In return, Humacyte will pay Fresenius low-single-digit royalties on net sales of Symvess outside the U.S., after a two-year royalty-free period following launch in each country, while existing U.S. royalty rates from mid-single digits to low double digits remain in place and Fresenius stays obligated to adopt Symvess as a standard of care where supported. Humacyte highlights that this realignment supports its planned international expansion and potential indication-specific partnerships, while Symvess currently holds FDA approval only for extremity vascular trauma and remains investigational for other uses.
Humacyte, Inc. entered a Third Amendment to its distribution agreement with Fresenius Medical Care, giving Humacyte the sole right to develop, manage regulatory matters for, and commercialize its 6 millimeter acellular tissue engineered vessel, branded Symvess, on a worldwide basis.
In return, Humacyte will pay Fresenius low-single-digit royalties on net sales of Symvess outside the U.S., after a two-year royalty-free period following launch in each country, while existing U.S. royalty rates from mid-single digits to low double digits remain in place and Fresenius stays obligated to adopt Symvess as a standard of care where supported. Humacyte highlights that this realignment supports its planned international expansion and potential indication-specific partnerships, while Symvess currently holds FDA approval only for extremity vascular trauma and remains investigational for other uses.
Humacyte, Inc. is raising $20 million through a registered direct offering of 25,000,000 shares of common stock at $0.80 per share. After placement fees and expenses, net proceeds are expected to be about $18.4 million.
The cash will support commercialization of Symvess in the vascular trauma indication, a planned Biologics License Application supplement for a hemodialysis use, related Phase 3 activities, broader pipeline development, and general corporate purposes. The offering, led by institutional investors, is expected to close on or about March 20, 2026, subject to customary conditions.
Humacyte, Inc. is raising $20 million through a registered direct offering of 25,000,000 shares of common stock at $0.80 per share. After placement fees and expenses, net proceeds are expected to be about $18.4 million.
The cash will support commercialization of Symvess in the vascular trauma indication, a planned Biologics License Application supplement for a hemodialysis use, related Phase 3 activities, broader pipeline development, and general corporate purposes. The offering, led by institutional investors, is expected to close on or about March 20, 2026, subject to customary conditions.
Humacyte, Inc. reported a material event on an Form 8-K documenting Amendment No. 2 to a Revenue Interest Purchase Agreement executed on September 17, 2025. The amendment names the parties as Humacyte Global, Inc., Humacyte, Inc. and the purchasers TPC Investments III LP, TPC Investment Solutions LP and Hook SA LLC.
The filing indicates the inclusion of the amendment as an exhibit and an Inline XBRL cover page file. No financial terms, changes to covenants, or quantitative impacts were disclosed in the provided text, so the filing primarily records the contractual amendment rather than operational results.